April 23, 2021 11:18 AM EDT

J&J's Tremfya scores 5-year psoriasis win in AAD data dump; Roche, Regeneron drugs among latest to earn EU advisory group's nod

Josh Sullivan

Max Gelman

Senior Editor

Kyle Blankenship

In the heated psoriasis market, every player is looking for a leg up. Now, J&J has long-term efficacy data showing positive results for Tremfya after …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J's Tremfya scores 5-year psoriasis win in AAD data dump; Roche, Regeneron drugs among latest to earn EU advisory group's nod

Josh Sullivan

Max Gelman

Senior Editor

Kyle Blankenship

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

Exclusive: Florida cancer biotech raises $100M Series A

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

PDUFAs for Tonix and Nuvation; Sanofi vaccine partnership; RAPT allergy deal

J&J's Trem­fya scores 5-year pso­ri­a­sis win in AAD da­ta dump; Roche, Re­gen­eron drugs among lat­est to earn EU ad­vi­so­ry group's nod

Senior Editor

Sign up to read this article for free.

more like this

J&J's Tremfya scores 5-year psoriasis win in AAD data dump; Roche, Regeneron drugs among latest to earn EU advisory group's nod